After gaining FDA approvals in 2015 and 2019 for Lonsurf, Servier and Taiho Oncology are due for a third nod this year for the cancer treatment. Based on data ...

Throughout the whirlwind COVID-19 vaccine rollouts in the U.S., federal officials have kept a close eye on reports of adverse events. Now, after tracking potential st...

In a surprising move, GSK recently pulled multiple myeloma therapy Blenrep off the U.S. market just 15 days after the drug flunked a confirmatory trial. The product p...

Eli Lilly is entering 2023 still riding a high from last year. Amid an expansion spree thanks to launches such as Mounjaro in diabetes, the company is gearing ...

With many of the world’s top-selling drugs speeding toward patent expirations over the next few years, pharmaceutical companies are hurrying to identify replacements....

As AstraZeneca fights to defend its aging two-drug inhaler Symbicort against generics, the company has a new approval to bolster its respiratory business. Wedn...

Last month, POCN, the largest network of physician associates and nurse practitioners, launched the first HIV Center of Excellence in conjunction with HIV Awareness M...

It’s near the end of the game and Astellas is running out of timeouts as it tries to stave off generic competition for its scanning agent Lexiscan. Last week, ...

In a closely watched patent dispute playing out at the U.S. Supreme Court, Amgen has drummed up support from fellow drugmakers large and small, plus industry associat...

Novartis has decided to end a classic generic pay-for-delay legal battle with a series of settlements. The Swiss pharma will pay altogether $245 million in sep...